Human Inhibin beta A chain(INHBA) Recombinant Protein

Description of Human Inhibin beta A chain(INHBA) Recombinant Protein

Introduction

Human Inhibin beta A chain (INHBA) is a protein that plays a critical role in regulating various biological processes, including cell growth, differentiation, and development. It is a member of the transforming growth factor-beta (TGF-β) superfamily and is primarily produced by the gonads and placenta. INHBA has been identified as a potential drug target due to its involvement in various diseases and disorders. In this article, we will provide a scientific description of the structure, activity, and application of Human Inhibin beta A chain recombinant protein.

Structure of INHBA

INHBA is a homodimeric protein consisting of two identical subunits, each with a molecular weight of approximately 18 kDa. The subunits are linked by disulfide bonds and form a complex with another protein, the inhibin alpha chain, to form the inhibin A heterodimer. The crystal structure of INHBA has been determined, revealing a compact globular structure with a central hydrophobic core and several loops and helices on the surface. This unique structure allows INHBA to interact with its receptors and modulate various signaling pathways.

Activity of this protein

INHBA acts as a negative regulator of follicle-stimulating hormone (FSH) secretion from the pituitary gland. It does this by binding to its specific receptor, the activin type II receptor (ActRII), and activating downstream signaling pathways. This leads to the inhibition of FSH production and subsequently affects the growth and development of ovarian follicles. INHBA also has a role in regulating bone formation and remodeling through its interaction with the bone morphogenetic protein (BMP) signaling pathway.

In addition to its endocrine functions, INHBA has been implicated in various diseases and disorders. For example, increased levels of INHBA have been observed in patients with polycystic ovary syndrome (PCOS), a common endocrine disorder in women. INHBA has also been linked to the development and progression of certain cancers, including breast, prostate, and ovarian cancer. In these cases, INHBA acts as a tumor promoter by promoting cell proliferation and inhibiting apoptosis.

Application of INHBA Recombinant Protein

Due to its involvement in various diseases and disorders, INHBA has emerged as a potential drug target. Recombinant INHBA protein has been produced using various expression systems, including bacteria, yeast, and mammalian cells. This recombinant protein can be used in both in vitro and in vivo studies to investigate the role of INHBA in different biological processes and diseases.

One potential application of INHBA recombinant protein is in the treatment of PCOS. Studies have shown that inhibin A levels are elevated in women with PCOS, and targeting INHBA with specific inhibitors has been proposed as a potential therapeutic strategy. Recombinant INHBA protein can be used to screen and identify potential inhibitors of INHBA, which could then be developed into drugs for the treatment of PCOS.

Another potential application of INHBA recombinant protein is in cancer therapy. As mentioned earlier, INHBA has been implicated in the development and progression of various cancers, making it a potential target for anti-cancer drugs. Recombinant INHBA protein can be used to study the mechanisms of INHBA in cancer and identify potential inhibitors that can be developed into targeted therapies.

In conclusion, Human Inhibin beta A chain recombinant protein is a critical protein involved in regulating various biological processes and has emerged as a potential drug target. Its unique structure and activity make it an attractive candidate for drug development, particularly in the treatment of PCOS and cancer. Further research and development of INHBA inhibitors may lead to the development of novel and effective treatments for these diseases.